Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

Tuesday, July 26, 2022

Read the Story Here

Related Publications

Discover more publications from our trials.

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

Sep 5, 2024

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab- Paclitaxel in Patients with Advanced Solid Tumors

Sep 5, 2024

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

Aug 23, 2024

Dr. Minal Barve
See All Posts